Product Name: Zenapax [daclizumab]
Date of Report: 3/21/2003
Phase: IV
A double-blind, placebo-controlled, randomized study to assess the efficacy and safety of Zenapax in combination with CellCept, cyclosporine, and corticosteroids in patients undergoing cardiac transplantation
Product Name: Zenapax [daclizumab]
Date of Report: To be Published
Phase: III
(Elite ReSpECT study) A Study of Zenapax (daclizumab) in Patients who have Undergone Liver Transplantation
Product Name: Zenapax [daclizumab]
Date of Report: 7/15/2005
Phase: III
Evaluation of renal function in liver transplant recipients receiving dacilizumab (Zenapax) and mycophenolate mofetil (CellCept, MMF) and a delayed lower dose of tacrolimus vs a standard dose tacrolimus-based regimen.
Product Name: Zenapax [daclizumab]
Date of Report: 1/1/2006
Phase: III
Multicenter, randomized, open trial, comparing the safety and efficacy of two administrations of Zenapax® versus Thymoglobulin®, both in combination with delayed introduction of Neoral®, CellCept® and steroids, in patients receiving their first renal transplantation
Product Name: Zenapax [daclizumab]
Date of Report: 6/4/2007
Phase: IV
Immune response to neoantigen and recall antigen in pediatric renal transplant recipients treated with the IL-2Rα monoclonal antibody, daclizumab (Zenapax).
